Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.65 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18042060 | 0.83 | TGFBR1 (0.92) | TGFBR1NAMPTMAPK14 | |
| SCHEMBL18041603 | 0.79 | TGFBR1 (0.59) | TGFBR1NAMPTKDM5BMAPK14 | |
| SCHEMBL18041474 | 0.77 | TGFBR1 (0.56) | TGFBR1NAMPTKDM5BMAPK14 | |
| SCHEMBL68360 | 0.74 | MAPK13 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL19806550 | 0.73 | TGFBR1 (0.51) | TGFBR1NAMPTKDM5B | |
| SCHEMBL18042075 | 0.72 | TGFBR1 (0.71) | TGFBR1NAMPTMAPK14 | |
| SCHEMBL27399209 | 0.72 | TGFBR1 (0.60) | TGFBR1NAMPTMAPK14 | |
| SCHEMBL1830448 | 0.70 | DYRK1A (0.71) | TGFBR1 | |
| SCHEMBL21401310 | 0.70 | TGFBR1 (0.53) | TGFBR1 | |
| SCHEMBL19806386 | 0.70 | TGFBR1 (0.50) | TGFBR1NAMPTKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885NAMPT 756/4885KDM5B 1367/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885NAMPT 756/4885KDM5B 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.